The Pharma Industry Dilemma

The regulatory agencies have so far been on top of these developments. Their dilemma too is that while they can regulate the approval of drugs from trials adjusted to smaller genotypically enriched populations. 

The large number of human SNPs has so far seldom shown the way to a new drug target, but this may change as we learn about polygenic complex diseases. 

Pharmacogenomics is here to stay and provides a useful contribution to the development of new drugs in diseases for which we have no medicines, and, for other diseases, new, safer, and more efficacious drugs. This, hopefully, will justify the already made large financial investments and will also justify the enormous efforts needed by many players in society to limit its potentially harmful uses outside of the narrower, well-regulated area of drug therapy. 

Meanwhile, the small-scale, individual, and disease-related genotyping is becoming part of the practice of modem medicine, to the clear benefit of everyone. 

More Tablets Taken PER Day than Meals Served Changing THE Industrial and Legislative Status Quo 

---